News
Four New Molecular Subgroups of Pancreatic Neuroendocrine Neoplasms Identified
Identification of four molecular subgroups of pancreatic neuroendocrine neoplasms (PNENs) with potential implications on patient stratification and treatment.
Filling in the gaps: GapPredict can complement repertoire of tools used to resolve missing DNA sequences in genome assemblies
GapPredict, the latest bioinformatics innovation from the GSC’s Birol Lab, uses deep learning to predict missing DNA bases in the gaps of [short-read] genome assemblies
Straglr: a new software tool for targeted genotyping and repeat expansion detection
Researchers in the lab of Dr. Inanç Birol, GSC Distinguished Scientist, develop Straglr, a new software tool for targeted genotyping and repeat expansion detection.
GSC researchers develop new method of single-cell RNA sequencing
A new method of single-cell RNA sequencing allows for high-throughput, full-length, strand-specific sequencing of transcripts.
Tumor sequencing panel screens for both somatic and germline changes of clinical significance
The GSC has developed a next-generation sequencing test that can identify both acquired and inherited gene changes in tumor tissue. A paper published in the Journal of Molecular Diagnostics explains how this information can be used in the clinical management of patients with advanced cancers and their families.
A novel transcriptome-based clinical assay allows for improved risk group stratification of acute myeloid leukemia patients
In a new study published in Nature Communications, GSC researchers used the power of next generation sequencing technologies to develop a clinical test that improves acute myeloid leukemia patient stratification.
Dr. Marco Marra joins Canada’s Medical Hall of Fame
Today, six outstanding individuals were inducted into the Canadian Medical Hall of Fame. Among them, Dr. Marco Marra, Director of Canada’s Michael Smith Genome Sciences Centre at BC Cancer. Visit the Canadian Medical Hall of Fame website to view the 2020 Induction Ceremony
A new method for analyzing silenced genes
Cancers are diseases of the genome. They can result from minor changes to single or a few base pairs, known as mutations, or from larger structural changes to the genome, including how it is packaged into chromosomes and manipulated by other molecules. Understanding how things have gone wrong in specific cancers can help scientists develop better prognostic tools and treatment strategies.
Pediatric case study demonstrates value in whole genome sequencing for cancer treatment planning
Whole genome sequencing allows for the identification of novel genomic alterations that are not detected by standard clinical techniques. In some cases, identification of these features can reveal therapeutic options for patients with otherwise untreatable cancers.